Published in J Recept Res on January 01, 1987
Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem (1995) 4.53
Production of a chronic arthritis with ovalbumin. Its retention in the rabbit knee joint. Ann Rheum Dis (1971) 3.73
(-)Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor. Nature (1980) 3.33
Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol (1996) 2.82
Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) (1997) 2.31
The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol (2003) 2.12
Bicuculline-insensitive GABA receptors on peripheral autonomic nerve terminals. Eur J Pharmacol (1981) 1.94
Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J (1995) 1.93
Possible involvement of nitric oxide in long-term potentiation. Eur J Pharmacol (1991) 1.72
Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci (1995) 1.68
Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor. FEBS Lett (1993) 1.62
Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem (1996) 1.60
A potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor. Life Sci (1992) 1.56
An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem (1995) 1.54
Cannabinoid-receptor expression in human leukocytes. Eur J Biochem (1993) 1.53
Subcellular localization of peripheral benzodiazepine receptors on human leukocytes. Lab Invest (1994) 1.50
Primary structure and functional expression of mouse pituitary and human brain corticotrophin releasing factor receptors. FEBS Lett (1993) 1.48
Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors. Naunyn Schmiedebergs Arch Pharmacol (1995) 1.43
The mobile lithotriptor: an answer for the smaller centre. Br J Urol (1993) 1.43
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med (2016) 1.41
Therapeutic advances in amyotrophic lateral sclerosis. Trends Pharmacol Sci (1997) 1.40
Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology (Berl) (1996) 1.40
Functional identification of rat atypical beta-adrenoceptors by the first beta 3-selective antagonists, aryloxypropanolaminotetralins. Br J Pharmacol (1996) 1.32
Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett (1996) 1.32
Peripheral benzodiazepine binding sites: effect of PK 11195, 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide. I. In vitro studies. Life Sci (1983) 1.31
The immunosuppressant SR 31747 blocks cell proliferation by inhibiting a steroid isomerase in Saccharomyces cerevisiae. Mol Cell Biol (1996) 1.30
Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J Clin Invest (1993) 1.28
Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest (1996) 1.28
Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol (1993) 1.27
The non-passage of mycobacteria from Freund's complete adjuvant granuloma depots to arthritic joints. Br J Exp Pathol (1975) 1.26
Altered synaptic plasticity and memory formation in nitric oxide synthase inhibitor-treated rats. Proc Natl Acad Sci U S A (1993) 1.25
Differentiation between two ligands for peripheral benzodiazepine binding sites, [3H]RO5-4864 and [3H]PK 11195, by thermodynamic studies. Life Sci (1983) 1.25
Immunoassay for urothelial cancers that detects DNA replication protein Mcm5 in urine. Lancet (1999) 1.24
Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. Biochim Biophys Acta (1996) 1.23
Involvement of peripheral benzodiazepine receptors in the protection of hematopoietic cells against oxygen radical damage. Blood (1996) 1.21
In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br J Pharmacol (1998) 1.18
Riluzole series. Synthesis and in vivo "antiglutamate" activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines. J Med Chem (1999) 1.18
Labelling of peripheral-type benzodiazepine binding sites in human brain with [3H]PK 11195: anatomical and subcellular distribution. Brain Res Bull (1987) 1.17
Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. Mol Psychiatry (2004) 1.16
Vesicouterine fistula: MRI diagnosis. Eur Radiol (1999) 1.15
Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci (1998) 1.14
Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int (2007) 1.14
Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system. J Pharmacol Exp Ther (1998) 1.14
Purification and characterization of the human SR 31747A-binding protein. A nuclear membrane protein related to yeast sterol isomerase. J Biol Chem (1997) 1.13
Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J Pharmacol Exp Ther (1997) 1.12
Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Lett (1995) 1.10
Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci (1996) 1.10
Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A. J Biol Chem (1996) 1.09
Characterization of two cloned human CB1 cannabinoid receptor isoforms. J Pharmacol Exp Ther (1996) 1.08
Electrophysiological and pharmacological characterization of peripheral benzodiazepine receptors in a guinea pig heart preparation. Life Sci (1984) 1.08
Distribution profile and properties of peripheral-type benzodiazepine receptors on human hemopoietic cells. Life Sci (1993) 1.06
Evidence for nerve growth factor-potentiating activities of the nonpeptidic compound SR 57746A in PC12 cells. J Neurochem (1995) 1.04
Multiple benzodiazepine receptors: evidence of dissociation between anticonflict and anticonvulsant properties by PK 8165 and PK 9084 (two quinoline derivatives). Life Sci (1981) 1.04
Baclofen: a selective agonist for a novel type of GABA receptor proceedings. Br J Pharmacol (1979) 1.03
Labelling of "peripheral-type" benzodiazepine binding sites in the rat brain by using [3H]PK 11195, an isoquinoline carboxamide derivative: kinetic studies and autoradiographic localization. J Neurochem (1983) 1.03
Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Sci (1996) 1.03
Riluzole, a novel antiglutamate, prevents memory loss and hippocampal neuronal damage in ischemic gerbils. J Neurosci (1989) 1.03
2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--II. Biochemical properties. Neuropharmacology (1985) 1.02
Peripheral benzodiazepine binding sites: effect of PK 11195, 1-(2-chlorophenyl)-N-methyl-(1-methylpropyl)-3 isoquinolinecarboxamide. II. In vivo studies. Life Sci (1983) 1.00
Are antihistamines sedative via a blockade of brain H1 receptors? J Pharm Pharmacol (1979) 1.00
Combined treatment with ketoconazole and luteinising hormone releasing hormone analogue: a novel approach to resistant progressive prostatic cancer. Br Med J (Clin Res Ed) (1983) 0.99
2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--I. Anticonvulsant properties. Neuropharmacology (1985) 0.98
Prostatic cancer: treatment with long-acting LHRH analogue. Br J Urol (1983) 0.98
Electrophysiological and pharmacological evidence that peripheral type benzodiazepine receptors are coupled to calcium channels in the heart. Life Sci (1985) 0.98